Following studies using genetic mouse models with a knockout (KO) system demonstrated that FXR controls the lipid and glucose metabolism, which may depend on pathophysiologic conditions; the FXR activation inhibits hyperglycemia and dyslipidemia in metabolic disease states, but it also contributes to normal glucose production in fasting conditions [5]. Here, NR1H4 is linked to metabolic disease.